Literature DB >> 24002384

Ischemic Charcot foot: different disease with different treatment?

L M Palena1, E Brocco, S Ninkovic, A Volpe, M Manzi.   

Abstract

AIM: Aim of the study was to describe the presence of peripheral arterial disease in combination with Charcot neuroarthropathy in diabetic patients, and to evaluate the role of revascularization supporting surgical and orthopedic treatment.
METHODS: We retrospectively collected and analyzed data of all diabetic patients affected by Charcot neuroarthropathy in combination with critical limb ischemia, which arrived to our care for the presence of foot lesions and underwent endovascular revascularization, followed by surgical and orthopedic treatment between January 2010 and January 2012. The primary end point was to assess the limb salvage rate. The secondary end point was to evaluate the healing time of the lesions.
RESULTS: Ten diabetic patients (10 men; mean age 69.1±8.5 years), affected by ischemic Charcot neuroarthropathy underwent endovascular revascularization, surgical debridement and orthopedic correction. The limb salvage rate was 90%, avoiding major amputation in 9 patients. In one patient (10%) the infection could not be controlled and below-the-knee amputation was carried out. The required time to heal the lesion was in mean 197.4±22.4 days, after revascularization, surgical and orthopedic treatment.
CONCLUSION: Patients with Charcot foot deformity can be affected by critical limb ischemia and revascularization therapy is necessary, to support surgical and orthopedic treatment, avoiding amputation and leading to limb and foot salvage.

Entities:  

Mesh:

Year:  2013        PMID: 24002384

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  1 in total

1.  Missing the boat: fatal ending to a missed case of Charcot arthropathy.

Authors:  Anna Luiza Galeazzi Rech; Yvon Stüve; Andreas Toepfer; Katrin E Schimke
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.